Assuntos
Nedocromil/farmacologia , Células Th1/efeitos dos fármacos , Células Th2/efeitos dos fármacos , Animais , Humanos , Interleucina-6/biossíntese , Cooperação Linfocítica/efeitos dos fármacos , Macrófagos Alveolares/efeitos dos fármacos , Macrófagos Alveolares/metabolismo , Ratos , Fator de Necrose Tumoral alfa/metabolismoAssuntos
Canais de Cloreto/efeitos dos fármacos , Ativação do Canal Iônico/efeitos dos fármacos , Nedocromil/farmacologia , Células 3T3/efeitos dos fármacos , Animais , Linhagem Celular , Canais de Cloreto/fisiologia , Cromolina Sódica/farmacologia , Cães , Soluções Hipotônicas , Leucemia Basofílica Aguda/patologia , Mastócitos/efeitos dos fármacos , Camundongos , Ratos , Cloreto de Sódio/antagonistas & inibidores , Células Tumorais CultivadasAssuntos
Brônquios/patologia , Mastócitos/efeitos dos fármacos , Nedocromil/farmacologia , Fator de Necrose Tumoral alfa/biossíntese , Células 3T3/efeitos dos fármacos , Animais , Linhagem Celular , Epitélio/efeitos dos fármacos , Epitélio/metabolismo , Liberação de Histamina/efeitos dos fármacos , Mastócitos/metabolismo , Camundongos , RatosRESUMO
Nedocromil sodium is a new chemical entity. This compound is very hydrophilic and is well absorbed by tissues such as the lung but not by tissues with tight junctions such as the gut. This product is chemically different from all drugs currently used for the treatment of airway diseases. The in vitro effects of nedocromil sodium are reviewed. Nedocromil sodium is capable of blocking: 1) the chemotaxis of neutrophils; 2) the activation of macrophages and monocytes by IgE; 3) the release of histamine from mast cells; 4) the cytotoxicity of platelets; 5) the release of LTC4 from eosinophils. Nedocromil sodium thus seems to have an effect on each of the cells which are implicated in the allergic reactions. In animals, nedocromil sodium can block the immediate bronchoconstriction induced by an antigen, adenosine and neurokinin A. Nedocromil sodium can also block the increase in bronchial responsiveness induced by antigen exposure. Moreover, vascular permeability induced by ovalbumin is reduced by nedocromil sodium. In summary, nedocromil sodium demonstrated a significant inhibitory effect of inflammation in both in vivo and in vitro models.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Asma/tratamento farmacológico , Quinolonas/uso terapêutico , Adulto , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Plaquetas/efeitos dos fármacos , Ensaios Clínicos como Assunto , Humanos , Macrófagos/efeitos dos fármacos , Nedocromil , Neutrófilos/efeitos dos fármacos , Quinolonas/farmacologia , Pesquisa , OvinosRESUMO
Nedocromil sodium (Tilade) is a novel pyranoquinoline dicarboxylic acid, developed for the treatment of reversible obstructive airway disease (ROAD). The drug exhibits specific anti-inflammatory properties when administered topically to the airways. These properties are illustrated by the activity of the drug in a number of in vitro and in vivo models. Thus, in vitro, nedocromil sodium inhibits activation of, and mediator release from, a wide range of inflammatory cells (neutrophils, eosinophils, macrophages/monocytes, mast cells and platelets) in both animals and man, initiated by either specific or non-specific stimuli. In vivo, the drug is effective in models of anaphylactic bronchospasm, increased vascular permeability, cellular influx, late reaction and bronchial hyperreactivity. Although as yet the mechanism of action has not been fully clarified, nedocromil sodium (Tilade) has demonstrated unequivocal efficacy in the treatment of ROAD in controlled therapeutic studies of up to twelve weeks in duration.